Search Abstracts Program

Session 105   Poster Session Pediatric HIV Infection: Disease Progression and Responses to Therapy 4:30-6:30 pm 4E-F

Click on the to view the poster for an abstract.

805-W.	Polymorphisms in SDF-1 and CCR5 Promoters 59029 and 59353 but not in Promoter 59356 or CCR2 Impact on Disease Progression in HIV-Infected Children K. K. Singh*1, C. F. Barroga1, M. D. Hughes2, J. Chen2, C. Raskino2, and S. A. Spector1 1Univ. of California, San Diego and 2Harvard Sch. of Publ. Hlth., Boston, MA Add to Itinerary
806-W.	Rapid Progression of HIV-1 Infection in Infants Associated with CCR5 and not CXCR4 Co-Receptor Usage A. Ashraf1, S. Beddows1, H. Lyall2, M. McClure1, G. Taylor*1, and 2 1Imperial Coll. and 2St. Mary's Hosp. NHS Trust, London, UK Add to Itinerary
807-W.	TREC Response to Antiretroviral Therapy in HIV-Infected Children in the PENTA 5 Trial A. de Rossi1, N. Klein*2, D. De Forni1, A. Babiker3, A. S. Walker3, and D. M. Gibb3 for the PENTA Imunology Committee 1Padova, Italy; 2Inst. of Child Hlth. London, UK; and 3MRC Clin. Trials Unit London, UK Add to Itinerary
808-W.	Evaluation of Ritonavir (RTV) in Combination with Stavudine (d4T) and Lamivudine (3TC) in HIV-Infected Children in 4 Nigerian Centres E. Ekong*1, I. Grant-Isibor2, T. Igbu3, and A. Uwah3 1Nigerian Army Reference Hosp., Yaba; 2Lagos Univ. Teaching Hosp., Idi-Araba; and 3Central Med. Lab., Yaba, Lagos, Nigeria Add to Itinerary
809-W.	Difficulties to Achieve Suppression of Viral Replication in Vertically HIV-1-Infected Infants Early Treated with d4T+ddI+NFV -- The PENTA 7 Study A. Compagnucci*1, Y. Saidi1, M. L. Chaix2, C. Rouzioux2, D. M. Gibb3, C. Giaquinto4, and A. Faye5 for the PENTA 7 Committees. 1INSERM SC10, Villejuif, France; 2Hosp. Necker, Paris, France; 3CTU MRC, London, UK; 4Univ. of Padova, Italy; and 5Hosp. R. Debré, Paris, France Add to Itinerary
810-W.	Salvage Therapy with Lopinavir-Ritonavir (Kaletra) in Heavily Pretreated Children J. T. Ramos*1, P. Carreño1, C. Fortuny2, M .D. Gurbindo3, M. L. Navarro3, M. I. De José4, I. Pocheville5, L. Ciria6, J. Dueñas6, P. Martín-Fontelos7, M. Gracia8, R. Gónzalez-Montero9, J. M. Bellón3, M. Munoz-Fernández3, and E. Cabrero10 1Hosp. 12 Octubre, Madrid; 2Hosp. Sant Joan de Deu; 3Hosp. G. Marañón; 4Hosp. La Paz; 5Hosp. Cruces; 6Hosp. Son Dureta, 7Hosp.Carlos III; 8Hosp. Clin., Zaragoza; 9Hosp. Sant Joan, Alicante; and 10Abbott Labs., Spain Add to Itinerary
811-W.	Genotypic and Phenotypic Resistance to BMS232632 (Atanazivir-ATV), among Heavily Experienced Pediatric Patients Who Were ATV-Naïve G. Aldrovandi*1, P. Samson2, T. Fenton2, S. Schnittman3, and R. Rutstein4 for the P1020A Team 1Univ. of Alabama, Birmingham; 2Harvard Univ., Boston, MA; 3Bristol-Myers Squibb, Wallingford, CT; and 4Univ. of Pennsylvania, Philadelphia Add to Itinerary
812-W.	HIV-1 Evolution during Effective HAART L. M. Frenkel, Y. Wang*, J. McKernan, A. J. Melvin, S. DeVange, G. M. Ellis, K. M. Mohan, G. L. Sylva, L. Heath, M. Mahalanabis, W. E. Naugler, I. A. Beck, P. Lewis, G. H. Learn, and J. Mullins Univ. of Washington, Seattle and Oregon Health Sci. Univ., Portland Add to Itinerary
813-W.	The Impact of HIV-1 Subtypes on Virological Response and Emergence of Resistance in the PENTA 5 Trial D. Pillay*1, A. S. Walker2, D. M. Gibb2, A. de Rossi3, S. Kaye2, M. Ait-Khaled4, M. Munoz-Fernandez5, and A. Babiker2 for the PENTA Steering Committee 1Univ. of Birmingham, UK; 2Univ. of London, UK; 3Univ. of Padova, Italy; 4GlaxoSmithKline, London, UK; and 5Hosp. Gen. Univ., Madrid, Spain Add to Itinerary

---